In his 43 years of practice, Randolph S. Sherman, Former Chair of Kaye Scholer’s Litigation Department, has handled a wide variety of complex litigation, including products liability, antitrust, false advertising, trademarks, trade dress, derivatives, insurance, employment discrimination and contract disputes, for clients such as Novartis, CIBA Vision, R.J. Reynolds Tobacco Company, Texaco Inc., W.R. Grace and The Walt Disney Company.
Throughout his career, Randy has been nationally recognized for his expertise in numerous publications, including Legal 500 US in 2007, which noted that he is “admired by clients for his litigation acumen, presence, dedication and tenacity.” Chambers USA 2007 noted that Randy is “a great oral advocate” and “a tireless worker” whose clients “think the world of him,” while Legal 500 2008 described Randy as “a real strategic thinker.” Chambers USA 2010 described him as “a walking encyclopedia of law,” and Chambers USA 2011 referenced Randy as an “exceptional litigator” who is “noted for his broad antitrust experience as well as his experience in product liability and IP matters.”
Randy has consistently been recognized by his peers as one of the Best Lawyers in America for antitrust litigation, which has been echoed by Chambers USA: America’s Leading Lawyers for Business 2007–2011. Additionally, Randy was most recently recognized for his expertise while being named a 2012 “Life Science Star” in the inaugural issue of Euromoney’s LMG Life Sciences Guide. From 2000–2007, Randy was national coordinating counsel for Novartis in the phenylpropanolamine (“PPA”) product liability litigation, and co-lead counsel for all the pharmaceutical company defendants in the MDL proceedings in that litigation. Novartis’s successful defense of the PPA cases was featured in “A Line in the Sand,” Litigation 2005 (ALM, Counsel Supp.).
Randy is also an accomplished appellate advocate, having argued appeals in the Second, Third, Fourth, Fifth, Eighth and Ninth Courts of Appeal. In PPA, he argued the prevailing position in the Ninth Circuit’s landmark ruling that MDL judges have extraordinary discretion to manage their dockets through dismissals for discovery noncompliance. In re Phenylpropanolamine (PPA) Products Liability Litigation, 460 F.3d 1217 (9th Cir. 2006).